Insider Transactions in Q1 2024 at Eli Lilly & CO (LLY)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
19
+0.12%
|
$14,478
$762.66 P/Share
|
|
Mar 18
2024
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.61%
|
$9,906
$762.66 P/Share
|
|
Mar 18
2024
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.03%
|
$11,430
$762.66 P/Share
|
|
Mar 18
2024
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.88%
|
$9,906
$762.66 P/Share
|
|
Mar 18
2024
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.49%
|
$9,906
$762.66 P/Share
|
|
Mar 11
2024
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
750
-8.69%
|
$564,750
$753.6 P/Share
|
|
Feb 20
2024
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.89%
|
$9,815
$755.66 P/Share
|
|
Feb 20
2024
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.62%
|
$9,815
$755.66 P/Share
|
|
Feb 20
2024
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
20
+0.13%
|
$15,100
$755.66 P/Share
|
|
Feb 20
2024
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.03%
|
$12,080
$755.66 P/Share
|
|
Feb 20
2024
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.5%
|
$9,815
$755.66 P/Share
|
|
Feb 16
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
169,684
-0.01%
|
$132,014,152
$778.8 P/Share
|
|
Feb 15
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
50,316
-0.02%
|
$38,290,476
$761.34 P/Share
|
|
Feb 12
2024
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Grant, award, or other acquisition
|
Direct |
5,363
+7.56%
|
$3,952,531
$737.26 P/Share
|
|
Feb 12
2024
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
2,369
+12.79%
|
$1,745,953
$737.26 P/Share
|
|
Feb 12
2024
|
Eric Dozier EVP, HR & Diversity |
BUY
Grant, award, or other acquisition
|
Direct |
1,336
+15.67%
|
$984,632
$737.26 P/Share
|
|
Feb 12
2024
|
Eric Dozier EVP, HR & Diversity |
SELL
Bona fide gift
|
Direct |
408
-6.52%
|
-
|
|
Feb 12
2024
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
12,910
+9.45%
|
$9,514,670
$737.26 P/Share
|
|
Feb 12
2024
|
Anat Ashkenazi EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,210
+9.05%
|
$3,102,770
$737.26 P/Share
|
|
Feb 12
2024
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,254
+12.69%
|
$924,198
$737.26 P/Share
|
|
Feb 12
2024
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
38,392
+7.42%
|
$28,294,904
$737.26 P/Share
|
|
Feb 12
2024
|
Anat Hakim EVP, GC & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,815
+16.02%
|
$4,285,655
$737.26 P/Share
|
|
Feb 12
2024
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
BUY
Grant, award, or other acquisition
|
Direct |
5,362
+10.74%
|
$3,951,794
$737.26 P/Share
|
|
Feb 12
2024
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,821
+8.68%
|
$2,079,077
$737.26 P/Share
|
|
Feb 12
2024
|
Ilya Yuffa EVP & President, LLY Int'l |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+19.48%
|
$3,530,230
$737.26 P/Share
|
|
Feb 12
2024
|
Alonzo Weems EVP, ERM & CECO |
BUY
Grant, award, or other acquisition
|
Direct |
951
+10.68%
|
$700,887
$737.26 P/Share
|
|
Feb 12
2024
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
1,668
+4.88%
|
$1,229,316
$737.26 P/Share
|
|
Feb 09
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
206,257
-0.03%
|
$153,042,694
$742.88 P/Share
|
|
Feb 08
2024
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
956
-0.22%
|
-
|
|
Feb 08
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
8,743
-0.01%
|
$6,469,820
$740.06 P/Share
|
|
Feb 01
2024
|
Anat Hakim EVP, GC & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,967
-7.39%
|
$1,268,715
$645.61 P/Share
|
|
Feb 01
2024
|
Anat Hakim EVP, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
4,442
+14.3%
|
-
|
|
Feb 01
2024
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
566
-1.8%
|
$365,070
$645.61 P/Share
|
|
Feb 01
2024
|
Johna Norton EVP, Global Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
1,268
+3.88%
|
-
|
|
Feb 01
2024
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
4,434
-3.85%
|
$2,859,930
$645.61 P/Share
|
|
Feb 01
2024
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
9,941
+7.94%
|
-
|
|
Feb 01
2024
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,844
-4.49%
|
$1,189,380
$645.61 P/Share
|
|
Feb 01
2024
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
BUY
Exercise of conversion of derivative security
|
Direct |
4,124
+9.13%
|
-
|
|
Feb 01
2024
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,240
-2.91%
|
$8,539,800
$645.61 P/Share
|
|
Feb 01
2024
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,611
+6.11%
|
-
|
|
Feb 01
2024
|
Ilya Yuffa EVP & President, LLY Int'l |
SELL
Payment of exercise price or tax liability
|
Direct |
1,664
-9.98%
|
$1,073,280
$645.61 P/Share
|
|
Feb 01
2024
|
Ilya Yuffa EVP & President, LLY Int'l |
BUY
Exercise of conversion of derivative security
|
Direct |
3,702
+18.17%
|
-
|
|
Feb 01
2024
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
1,844
-2.97%
|
$1,189,380
$645.61 P/Share
|
|
Feb 01
2024
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
4,124
+6.23%
|
-
|
|
Feb 01
2024
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,685
-10.9%
|
$1,086,825
$645.61 P/Share
|
|
Feb 01
2024
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,618
+18.96%
|
-
|
|
Jan 31
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
78,573
-0.0%
|
$51,386,742
$654.18 P/Share
|
|
Jan 30
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
76,215
-0.04%
|
$49,158,675
$645.69 P/Share
|
|
Jan 29
2024
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
54,032
-0.05%
|
$34,850,640
$645.07 P/Share
|
|
Jan 16
2024
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.58%
|
$9,510
$634.57 P/Share
|